Akeso, Summit Cancer Drug Confirms Lung Cancer Survival Benefit

Akeso, Summit cancer drug confirms lung cancer survival benefit

A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

Summit Therapeutics in focus as its lung cancer drug shows survival benefit

Summit Therapeutics (SMMT) jumps as Akeso reports Phase III HARMONi-2 OS win for ivonescimab vs Keytruda in NSCLC.

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

Summit is Conducting HARMONi-7 in Patients with PD-L1 High-Expressing NSCLC MIAMI–(BUSINESS WIRE)–$SMMT–Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) …

Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial

After an interim overall survival result last year that shook investor confidence, Akeso has claimed victory Thursday with updated Phase 3 data for its closely watched PD-1xVEGF bispecific in certain lung cancer patients. Akeso said ...

Akeso cancer trial meets overall survival endpoint against Pembrolizumab

Biopharmaceutical company Akeso announced its Phase III HARMONi-2 trial met its overall survival endpoint, demonstrating clinical benefits for lung cancer patients compared to Pembrolizumab.

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC

HONG KONG, Sept. 3, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Data Monitoring Committee (IDMC), met...